Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 2:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 193 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: placebo naltrexone Clear all
Completed Phase 2Phase 3 Interventional Results available

Improving Treatment Outcomes for Prescription Opioid Dependence

NCT02543944
View directory record Official record
Conditions
Drug Dependence
Interventions
Gabapentin, Buprenorphine, Clonidine, Naltrexone (oral), Naltrexone (depot), Placebo
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Sep 10, 2026, 2:03 AM EDT
Terminated Phase 2 Interventional Results available

Naltrexone-Bupropion Versus Placebo-Bupropion for Weight Loss in Schizophrenia

NCT03132571
View directory record Official record
Conditions
Schizophrenia, Diabetes Mellitus, Type 2, Obesity
Interventions
Naltrexone, Bupropion, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Sep 10, 2026, 2:03 AM EDT
Completed Phase 2 Interventional Results available

Effects of Naltrexone on Nicotine Reinforcement

NCT00270231
View directory record Official record
Conditions
Tobacco Dependence
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 9, 2013 · Synced Sep 10, 2026, 2:03 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Better Than Study: Targeting Heavy Alcohol Use With Naltrexone Among Men Who Have Sex With Men (MSM)

NCT02330419
View directory record Official record
Conditions
Binge Drinking, HIV
Interventions
Placebo, Naltrexone, Medical Management (MM) counseling for alcohol use:, Urinalysis for novel alcohol biochemical markers:, Behavioral survey measurements:, Dried Blood Spot (DSB) Testing for Phosphatidylethanol, Ecological Momentary Assessment
Drug · Behavioral · Diagnostic Test
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years · Male only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2025 · Synced Sep 10, 2026, 2:03 AM EDT
Completed Phase 2 Interventional Results available

Naltrexone for Individuals of East Asian Descent

NCT02026011
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 65 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Sep 10, 2026, 2:03 AM EDT
Completed Phase 3 Interventional Results available

A Study of Embeda (Kadian NT, ALO-01) in Subjects With Pain Due to Osteoarthritis of the Hip or Knee

NCT00420992
View directory record Official record
Conditions
Osteoarthritis, Chronic Pain
Interventions
ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended Release), Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years and older
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
81
States / cities
Birmingham, Alabama • Mobile, Alabama • Peoria, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Sep 10, 2026, 2:03 AM EDT
Completed Not applicable Interventional Results available

Treatment of Binge Eating Disorder in Obesity: Naltrexone/ Bupropion Combination Versus Placebo

NCT02317744
View directory record Official record
Conditions
Binge Eating Disorder
Interventions
Naltrexone and bupropion combination, Pill Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 21, 2017 · Synced Sep 10, 2026, 2:03 AM EDT
Withdrawn Phase 4 Interventional

Evaluation of Naltrexone as a Treatment for Self-injurious Behavior

NCT02726035
View directory record Official record
Conditions
Self-injurious Behavior, Self Mutilation
Interventions
Naltrexone, Placebo
Drug · Other
Lead sponsor
Western Michigan University School of Medicine
Other
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 10, 2026, 2:03 AM EDT
Completed Phase 2 Interventional Results available

Investigation of Naltrexone for Pathological Gambling

NCT01057862
View directory record Official record
Conditions
Pathological Gambling
Interventions
Naltrexone, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
3
States / cities
Middletown, Connecticut • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Sep 10, 2026, 2:03 AM EDT
Completed Phase 2 Interventional Results available

Naltrexone in the Treatment of Trichotillomania

NCT00775229
View directory record Official record
Conditions
Trichotillomania
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Sep 10, 2026, 2:03 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Maintenance Therapy

NCT03047005
View directory record Official record
Conditions
Binge-Eating Disorder, Obesity
Interventions
NB medication (Naltrexone Bupropion combination), Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Sep 10, 2026, 2:03 AM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

Electromagnetic Immunotherapy Mapping and Cytokine Forecasting Study (QSIT)

NCT07221565
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis, Autoimmune Diseases, Chronic Inflammatory Syndromes, Immune Dysregulation
Interventions
Low-Frequency Electromagnetic Resonance Therapy (LF-EMR), Sham Resonance Device (Inactive Control), Low-Dose Naltrexone (LDN)
Device · Drug
Lead sponsor
Truway Health, Inc.
Industry
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 10, 2026, 2:03 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Efficacy of Naltrexone in Women's Smoking Cessation

NCT00271024
View directory record Official record
Conditions
Smoking, Smoking Cessation
Interventions
Naltrexone (drug), Placebo (for Naltrexone)
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
333 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Sep 10, 2026, 2:03 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Safety and Efficacy of Naltrexone and Scopolamine Utilized in the Treatment of Major Depression

NCT03386448
View directory record Official record
Conditions
Depression
Interventions
Scopolamine and naltrexone, placebo arm
Drug
Lead sponsor
The Taub Group
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated May 19, 2019 · Synced Sep 10, 2026, 2:03 AM EDT
Terminated Phase 2 Interventional Results available

Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19

NCT04365985
View directory record Official record
Conditions
COVID-19, Acute Respiratory Distress Syndrome, Severe Acute Respiratory Syndrome (SARS), Coronavirus Infections
Interventions
Naltrexone, Ketamine, Placebo
Drug · Other
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Sep 10, 2026, 2:03 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Pharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1)

NCT04599478
View directory record Official record
Conditions
Loss-of-control Eating, Obesity/Overweight
Interventions
Naltrexone and Bupropion medication, Behavioral Weight Loss, Placebo
Drug · Behavioral · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 10, 2026, 2:03 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate Withdrawal Effects Following Dosing of Oxycodone/Naltrexone in Methadone-Maintained Subjects

NCT02391571
View directory record Official record
Conditions
Withdrawal Symptoms
Interventions
Oxycodone/Naltrexone Capsules, Oxycodone, Placebo
Drug
Lead sponsor
Elite Laboratories, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2016 · Synced Sep 10, 2026, 2:03 AM EDT
Completed Phase 4 Interventional Results available

Naltrexone for Heavy Drinking in Young Adults

NCT00568958
View directory record Official record
Conditions
Alcohol Consumption, Alcoholic Intoxication, Alcoholism, Alcohol-induced Disorders
Interventions
BASICS counseling, naltrexone, placebo naltrexone
Behavioral · Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 25 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 29, 2020 · Synced Sep 10, 2026, 2:03 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Naltrexone and Varenicline: Weight Gain and Tolerability in Cigarette Smokers

NCT00502216
View directory record Official record
Conditions
Smoking, Nicotine Dependence
Interventions
Naltrexone, Varenicline
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Sep 10, 2026, 2:03 AM EDT
Withdrawn Phase 2 Interventional

Treatment of Chronic Itch in Atopic Dermatitis With Opioid Antagonist Naltrexone

NCT04325802
View directory record Official record
Conditions
Atopic Dermatitis, Pruritus, Pruritus Chronic, Dermatitis
Interventions
Naltrexone, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Sep 10, 2026, 2:03 AM EDT
Withdrawn Phase 2 Interventional

Treatment of Chronic Itch in Atopic Dermatitis With Topical Naltrexone

NCT04154033
View directory record Official record
Conditions
Atopic Dermatitis, Pruritus, Dermatitis
Interventions
Naltrexone, Placebo Cream
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Sep 10, 2026, 2:03 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Memantine as a Supplement to Naltrexone in Treating Heroin Dependence

NCT00476242
View directory record Official record
Conditions
Opioid Dependence, Heroin Dependence
Interventions
Vivitrol, memantine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Sep 10, 2026, 2:03 AM EDT
Completed Phase 2 Interventional Results available

Effect of Topical Naltrexone Ophthalmic Solution on the Signs and Symptoms of Dry Eye in Diabetic Subjects

NCT03660475
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Naltrexone, Placebos
Drug
Lead sponsor
Sassani, Joseph S., MD, MHA
Individual
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Sep 10, 2026, 2:03 AM EDT
Completed Phase 2 Interventional Results available

N-Acetyl Cysteine Plus Naltrexone in Methamphetamine Dependence

NCT00332605
View directory record Official record
Conditions
Methamphetamine Dependence
Interventions
Naltrexone plus N-Acetyl Cysteine, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Sep 10, 2026, 2:03 AM EDT